Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.48 |
| ▸ | POLRMT | O00411 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.31 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26755222 | 0.94 | TMPRSS2 (0.48) | TMPRSS2POLRMTRIPK1 | |
| SCHEMBL24790426 | 0.93 | TMPRSS2 (0.46) | TMPRSS2POLRMTRIPK1RNASEL | |
| SCHEMBL27120903 | 0.91 | TMPRSS2 (0.48) | TMPRSS2POLRMTRIPK1 | |
| SCHEMBL24313286 | 0.90 | TMPRSS2 (0.50) | TMPRSS2POLRMTRIPK1 | |
| SCHEMBL24418869 | 0.90 | TMPRSS2 (0.43) | TMPRSS2 | |
| SCHEMBL25381757 | 0.90 | TMPRSS2 (0.47) | TMPRSS2POLRMTRIPK1 | |
| SCHEMBL23960047 | 0.90 | TMPRSS2 (0.47) | TMPRSS2POLRMTRIPK1 | |
| SCHEMBL25383763 | 0.89 | TMPRSS2 (0.53) | TMPRSS2POLRMTRIPK1 | |
| SCHEMBL24917639 | 0.89 | TMPRSS2 (0.46) | TMPRSS2POLRMTRIPK1 | |
| SCHEMBL24916955 | 0.89 | TMPRSS2 (0.46) | TMPRSS2POLRMTRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297226-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20240317790-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2024-09-26 | — | — | US | disclosed |
| US-11814406-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | VIGONVITA LIFE SCIENCES CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | VIGONVITA LIFE SCIENCES CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| EP-4204421-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023102472-A1 | ANTIVIRAL PRODRUGS AND FORMULATIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2022142477-A1 | METHODS AND MODIFIED NUCLEOSIDES FOR TREATING CORONAVIRUS INFECTIONS | SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2022-07-07 | — | — | WO | disclosed |
| US-20220081462-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2022-03-17 | — | — | US | disclosed |
| WO-2021213288-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | 中国科学院上海药物研究所 (CN) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081462-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, ACE | TMPRSS2 141/4885POLRMT 20/4885RIPK1 3979/4885 |
| US-11814406-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, ACE | TMPRSS2 141/4885POLRMT 20/4885RIPK1 3979/4885 |
| US-12297226-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, ACE | TMPRSS2 141/4885POLRMT 20/4885RIPK1 3979/4885 |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, ACE | TMPRSS2 141/4885POLRMT 20/4885RIPK1 3979/4885 |
| US-20240317790-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, ACE | TMPRSS2 141/4885POLRMT 20/4885RIPK1 3979/4885 |
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | PNP, TYMP, PIGS | TMPRSS2 145/4885POLRMT 139/4885RIPK1 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.